CONMED Corp
No enriched coverage for $CNMD in the last 7 days.
No SEC Form 4 filings for $CNMD in the last 30 days.
See all $CNMD insider activity →CONMED (NYSE: CNMD) shares rose about 10.5% after the company reported Q2 adjusted EPS of $1.38 versus $1.15 a year earlier and above the $1.11 analyst estimate. CONMED also topped revenue expectations and raised full-year adjusted EPS guidance to $4.54 (midpoint) and revenue to $1.37B.
CONMED (NYSE:CNMD) reported Q2 CY2026 revenue of $343.5 million, flat year over year but 1.8% above Wall Street estimates. The company guided full-year revenue to about $1.37 billion. Non-GAAP adjusted EPS was $1.38, 24.3% above consensus, and the stock rose 5.7% to $45.73 after the report.
CONMED Corp (CNMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cnmdearningsrelease06302026.htm EX-99.1 Document NEWS RELEASE CONTACT : CONMED Corporation Investor Relations ir@conmed.com CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance Largo, Florida, July 29, 2026 – CONMED Corporati
Recent CNMD coverage spans financial news, earnings and mergers & acquisitions.
Raised guidance after an earnings beat is likely to sustain upward momentum, but the move is already large intraday.
The earnings beat and full-year revenue guidance near consensus, plus EPS beat, are likely to support near-term upside momentum, but margin contraction and flat revenue temper the quality of the beat.
Updated FY2026 guidance and Q2 performance provide a direct catalyst for CNMD’s near-term valuation and positioning.
Deal exploration headlines can drive a sharp repricing, but the article provides no confirmed bid terms or process timeline.
Analyst downgrade with lowered 2027 growth/EPS estimates is a near-term negative catalyst for CNMD sentiment and expectations.
alphai scores every news story that mentions CNMD with an AI model for sentiment and relevance, and aggregates insider trades from CONMED Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CONMED (NYSE: CNMD) shares rose about 10.5% after the company reported Q2 adjusted EPS of $1.38 versus $1.15 a year earlier and above the $1.11 analyst estimate. CONMED also topped revenue expectations and raised full-year adjusted EPS guidance to $4.54 (midpoint) and revenue to $1.37B.
6 min readCONMED (NYSE:CNMD) reported Q2 CY2026 revenue of $343.5 million, flat year over year but 1.8% above Wall Street estimates. The company guided full-year revenue to about $1.37 billion. Non-GAAP adjusted EPS was $1.38, 24.3% above consensus, and the stock rose 5.7% to $45.73 after the report.
6 min readCONMED Corp (CNMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cnmdearningsrelease06302026.htm EX-99.1 Document NEWS RELEASE CONTACT : CONMED Corporation Investor Relations ir@conmed.com CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance Largo, Florida, July 29, 2026 – CONMED Corporati
6 min readCONMED (NYSE: CNMD) shares rose about 9% after reports said the medical technology company is exploring a potential sale. The company is reportedly working with advisers to evaluate options, including a sale, after receiving interest from private equity firms. The article also notes BofA’s prior downgrade and revised 2027 growth and EPS estimates.
3 min readCONMED (NYSE:CNMD) shares fell about 4.9% after BofA Securities downgraded the stock to Underperform from Neutral, citing growth concerns. BofA cut its 2027 organic growth estimate to 4.5% from 5.8% and 2027 EPS to $4.54 from $4.67 (vs. $4.79 consensus), while keeping a $40 price target. Shares later traded around $34.26.
4 min readCONMED Corp (CNMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029501601ex10-1.htm LETTER AGREEMENT, DATED MAY 28, 2026, BY AND BETWEEN THE COMPANY AND JOHN E. GALLAGHER Exhibit 10.1 John D. Ferrell Executive Vice President, HR CONMED Corporation 11311 Concept Blvd. Largo, FL 33773 May 28, 2026 John Gallagher 331 Indian Trail Dri
3 min readCONMED Corp, a medical technology company, has released its latest quarterly figures, emphasizing continued growth in minimally invasive surgery and orthopedics. The company's core business revolves around surgical devices and disposables for hospitals, with key revenue drivers in sports medicine and advanced surgical devices. The outlook focuses on profitable growth, despite macroeconomic uncertainties and cost pressures, making it relevant for investors tracking healthcare trends and surgical innovation.
4 min readCONMED Corp (US2074101013) is a key player in surgical devices for minimally invasive procedures, particularly in orthopedics and general surgery, positioning it for steady growth due to aging populations and post-pandemic surgical rebounds. The company's business model focuses on R&D, market expansion, and efficient manufacturing, catering to high-growth segments like sports medicine and bariatric surgery. While facing competition from industry giants, CONMED's niche strategy, innovation in specialized devices, and strong presence in both U.S. and international markets are seen as strong advantages for investors.
4 min readCONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with its stock price declining and a negative stock return over the past year. Despite a fair valuation, its metrics show a mixed landscape compared to peers like Globus Medical and Sanmina, highlighting the competitive challenges within the industry. The company's current price is $39.90, down from $41.40, with a P/E ratio of 18 and a dividend yield of 155.87%.
3 min readCONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has undergone a valuation adjustment with a P/E ratio of 18 and a high dividend yield of 155.87%. The company's financial metrics include a Price to Book Value of 1.57, EV to EBIT of 16.64, EV to EBITDA of 11.96, ROCE of 7.88%, and ROE of 8.88%. This adjustment reflects its position within a competitive market, where it demonstrates a lower P/E ratio compared to some competitors while facing others rated more favorably.
3 min read
